Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus
Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus
复制标题
DOI：
10.5754/hge13832
复制
发表时间：
2014-03-01
影响因子：
--
通讯作者：
Chayama, Kazuaki
中科院分区：
文献类型：
--
作者：
Fukuhara, Takayuki;Hyogo, Hideyuki;Chayama, Kazuaki
背景/目的：二肽基肽酶 4 抑制剂可用于治疗 2 型糖尿病 (DM)。然而，尚未确定对非酒精性脂肪肝病（NAFLD）肝功能和葡萄糖代谢的影响。本研究的目的是评估西他列汀治疗患有 2 型糖尿病的 NAFLD 患者的疗效和安全性。方法：对 44 名经活检证实患有 NAFLD 并伴有 2 型糖尿病的患者进行了评估。患者接受西他列汀（50 毫克/天）治疗 12 个月。结果：治疗后糖化血红蛋白 (HbA1c) 较治疗前下降 0.7% (P = 7.5%)（r 分别 = 0.568 和 0.501）。结论：西他列汀治疗 NAFLD 合并 2 型糖尿病是安全的，并且显示出与 2 型糖尿病报道相似的抗糖尿病作用，根据 HbA1c 和转氨酶变化之间的相关性发现，严格血糖控制有助于 NAFLD 的改善。
Background/Aims: Dipeptidyl peptidase-4 inhibitor is useful for the treatment of type 2 diabetes mellitus (DM). However, effects on liver function and glucose metabolism in nonalcoholic fatty liver disease (NAFLD) have not been established. The objective of this study was to evaluate the efficacy and safety of sitagliptin in NAFLD patients with type 2 DM. Methodology: Forty-four patients with biopsy-proven NAFLD with type 2 DM were evaluated. Patients were administered sitagliptin (50 mg/day) for 12 months. Results: Hemoglobin A1c (HbA1c) decreased by 0.7% after treatment (P = 7.5%) group before treatment (r = 0.568, and 0.501, respectively). Conclusions: Sitagliptin for the treatment of NAFLD with type2 DM was safe and showed similar antidiabetic effects as reported for type 2 DM, suggesting that tight glycemic control would contribute to the improvement of NAFLD based from the findings of correlation between the changes of HbA1c and transaminases.